Ammon S et al. |
Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10848660
|
Leiper K et al. |
Open label trial of oral clarithromycin in active Crohn's disease. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10848665
|
Wheeldon TU et al. |
Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12848630
|
Perri F et al. |
Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421877
|
Huang J et al. |
Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:24117692
|
Molina-Infante J et al. |
Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. |
2010 |
Aliment. Pharmacol. Ther. |
pmid:20180787
|
Chacko Y and Holtmann GJ |
Helicobacter pylori eradication and weight gain: has it opened a Pandora's box? |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21679208
|
Zullo A et al. |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15948808
|
Dani R et al. |
Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10594400
|
Harris A |
The importance of clarithromycin dose in the management of H. pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10594406
|
Harb AH et al. |
Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:26011564
|
Spinzi G et al. |
Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9146769
|
Peterson WL |
The role of antisecretory drugs in the treatment of Helicobacter pylori infection. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9146787
|
Lehmann FS et al. |
Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10735923
|
Miwa H et al. |
Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10735925
|
Spinzi GC et al. |
Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10735926
|
Graham DY et al. |
Furazolidone combination therapies for Helicobacter pylori infection in the United States. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10651662
|
Veldhuyzen Van Zanten S et al. |
One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12786632
|
Wong BC et al. |
Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10651663
|
Fock KM et al. |
Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10651664
|
Fakheri H et al. |
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207517
|
Nagahara A et al. |
Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207518
|
Khurana R et al. |
Meta-analysis: Helicobacter pylori eradication treatment efficacy in children. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17305754
|
Tomita T et al. |
Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966543
|
Axon AT et al. |
Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042977
|
Labenz J et al. |
One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042978
|
Labenz J et al. |
Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042979
|
Calvet X et al. |
One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12144575
|
Cestari R |
Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infection. H. Pylori Lombardy Group. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9798804
|
Spadaccini A et al. |
Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9798805
|
Basset C et al. |
Helicobacter pylori infection: anything new should we know? |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15335411
|
Lionetti E et al. |
Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:17032283
|
Iijima K et al. |
Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15153171
|
O'Connor HJ et al. |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9570262
|
Scott BB |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9570263
|
Goodgame RW et al. |
Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11736715
|
Gudjonsson H et al. |
High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9845401
|
Cammarota G et al. |
High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15043520
|
Fraser AG |
Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28776748
|
Jung YS et al. |
Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28776746
|
Sheu BS et al. |
Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15691303
|
Wong WM et al. |
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16423001
|
Klok RM et al. |
Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966514
|
Broutet N et al. |
Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12492738
|
Tsuzuki T et al. |
Clarithromycin increases the release of heat shock protein B from Helicobacter pylori. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966545
|
Higuchi K et al. |
Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12492739
|
Coelho LG et al. |
Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12492742
|
Gisbert JP et al. |
Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:16268980
|
Ellenrieder V et al. |
Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9701524
|
Zullo A et al. |
Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication? |
2010 |
Aliment. Pharmacol. Ther. |
pmid:20518756
|